Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 18, 2007

Ambrx Allies with Merck & Co. in Type 2 Diabetes Drug Discovery Collaboration

  • Ambrx and Merck & Co. are collaborating on the development of a therapeutic protein with properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders.

    Both parties will utilize Ambrx' protein technology, ReCODE™, to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

    The collaboration includes an upfront and R&D payments from Merck. Additionally, Ambrx will be eligible to receive future milestone fees associated with research, development, and commercialization of a drug candidate along with royalties on net sales. The firm also has the right to exercise an end of Phase II profit sharing option.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.